0.17Open0.17Pre Close0 Volume935 Open Interest12.50Strike Price0.00Turnover949.99%IV46.30%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type0.1439Delta0.0866Gamma50.94Leverage Ratio-0.7929Theta0.0000Rho7.33Eff Leverage0.0006Vega
Annovis Bio Stock Discussion
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
Annovis Bio Inc. (NYSE: ANVS) has announced promising early research results for its lead drug, buntanetap, in combination with other approved drugs for Alzheimer's disease (AD) treatment. While recent FDA-approved drugs like Leqembi and Kisunla may slow cognitive decline in AD patients, they do not improve cognition. Similarly, GLP-1 drugs, origi...
Larger Image: tradingview.com...
$ANVS
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
Annovis Bio Inc. (NYSE: ANVS) has filed three new patents for innovative combination therapies involving its lead compound, buntanetap. These patents cover combinations of buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), or a combination of all three, aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's.
Recent preclinical studies ...
No comment yet